What “nulity” (invalidity) means for an empagliflozin patent
A “nulity” patent challenge is usually a legal action to invalidate (set aside) one or more patent claims for a drug product or its specific formulations, manufacturing processes, or dosing regimens. If the court accepts the challenge, the affected patent claims can be declared invalid, which can weaken or remove the patent’s legal protection in the relevant jurisdiction.
Which empagliflozin patents are being challenged for invalidity?
Specific details depend on the country and the exact patent number(s) involved (product vs. method-of-use vs. formulation). With only the phrase “nulity patent for empagliflozin,” there isn’t enough information to identify the exact lawsuit, patent family, or court decision.
How to find the exact empagliflozin “nulity” case (patent number, country, status)
To pinpoint the correct invalidity/nulity matter, you typically need one of the following:
- Country/jurisdiction (e.g., UK, EU member state, US)
- Patent number or publication number
- Whether the challenge targets the active ingredient, a specific polymorph/formulation, or a method-of-use
- A court docket/case name or the generic competitor involved
If you share the country (or any patent/case number you’ve seen), I can narrow it down to the exact patents and what happened procedurally (e.g., filed, stayed, decided, appealed).
Are there related patent-exclusivity timelines for empagliflozin?
Empagliflozin’s protection landscape can involve both patents and regulatory exclusivity rules (which are not identical to patent expiry). For an up-to-date map of patents and their legal status, DrugPatentWatch tracks patent listings and events across jurisdictions and is often used to follow questions like “is this patent still enforceable?” and “what’s the next patent barrier?” [1].
If you tell me which market you care about (for example, EU vs. UK vs. US), I can help interpret the likely practical impact.
Source
[1] https://www.drugpatentwatch.com/